Back

Pancreatic cancer stem cells (CSCs) are regulated via a feedback-loop of telomerase activity and stemness factors

Walter, K.; Rodriguez-Aznar, E.; Ventura-Ferreira, M. S.; Frappant, P. O.; Dittrich, T.; Tiwary, K.; Meessen, S.; Lerma, L.; Schulte, L. A.; Arnold, F.; Azoitei, N.; Erkan, M.; Lehel, A.; Bruemmendorf, T.; Seufferlein, T.; Kleger, A.; Tabares, E.; Guenes, C.; Beier, F.; Sainz, B.; Hermann, P. C.

2020-11-03 cancer biology
10.1101/2020.11.02.361931 bioRxiv
Show abstract

To date, it is still unclear how cancer stem cells (CSCs) regulate their stemness properties, and to what extent they share common features with normal stem cells. Telomerase regulation is a key factor in stem cell maintenance. In this study, we investigate how telomerase regulation affects cancer stem cell biology in pancreatic ductal adenocarcinoma (PDAC), and delineate the mechanisms by which telomerase activity and CSC properties are linked. Using primary patient-derived pancreatic cancer cells, we show that CSCs have higher telomerase activity and longer telomeres than bulk tumor cells. Inhibition of telomerase activity, using genetic TERT-knockdown or pharmacological inhibitor (BIBR1532) resulted in CSC marker depletion in vitro, and reduced tumorigenicity in vivo. Furthermore, we identify a positive feedback loop between stemness factors (KLF4, SOX2, OCT3/4, NANOG) and telomerase, which is essential for the self-renewal of pancreatic CSCs. Disruption the balance between telomerase activity and stemness factors, eliminates CSCs via induction of DNA damage and apoptosis, opening future perspectives to avoid CSC driven therapy resistance and tumor relapse in PDAC patients.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
eLife
● 5422 papers in training set
Top 7%
9.3%
2
Cell Reports
○ 1338 papers in training set
Top 6%
6.9%
3
Nature Communications
○ 4913 papers in training set
Top 34%
4.4%
4
Cell Death & Disease
○ 126 papers in training set
Top 0.2%
4.4%
5
Scientific Reports
○ 3102 papers in training set
Top 28%
4.2%
6
Cell Stem Cell
○ 57 papers in training set
Top 0.5%
3.6%
7
Stem Cell Reports
○ 118 papers in training set
Top 0.2%
3.6%
8
Gastroenterology
○ 40 papers in training set
Top 0.6%
3.3%
9
Stem Cells
◐ 28 papers in training set
Top 0.1%
3.3%
10
Cell Death & Differentiation
○ 48 papers in training set
Top 0.1%
3.1%
11
Cancers
○ 200 papers in training set
Top 2%
2.4%
12
EMBO Molecular Medicine
○ 85 papers in training set
Top 1%
2.1%
50% of probability mass above
13
Proceedings of the National Academy of Sciences
● 2130 papers in training set
Top 27%
2.1%
14
Journal of Experimental Medicine
● 106 papers in training set
Top 2%
2.1%
15
iScience
○ 1063 papers in training set
Top 10%
2.1%
16
Oncogenesis
○ 12 papers in training set
Top 0.1%
1.9%
17
Cancer Research
● 116 papers in training set
Top 2%
1.8%
18
Gut
● 36 papers in training set
Top 0.4%
1.8%
19
Cancer Cell
○ 38 papers in training set
Top 1%
1.5%
20
PLOS ONE
● 4510 papers in training set
Top 58%
1.4%
21
Developmental Cell
○ 168 papers in training set
Top 10%
1.2%
22
Frontiers in Cell and Developmental Biology
○ 218 papers in training set
Top 6%
1.1%
23
Molecular Cancer Research
● 42 papers in training set
Top 0.5%
1.0%
24
Cancer Letters
○ 32 papers in training set
Top 0.5%
1.0%
25
Cell Metabolism
○ 49 papers in training set
Top 2%
1.0%
26
Cancer Discovery
● 61 papers in training set
Top 1%
1.0%
27
EMBO reports
○ 136 papers in training set
Top 5%
0.9%
28
Communications Biology
○ 886 papers in training set
Top 18%
0.9%
29
JCI Insight
● 241 papers in training set
Top 6%
0.8%
30
Cancer Research Communications
● 46 papers in training set
Top 1%
0.8%